# US 2019/0169623 A1 · Methods and compositions to prevent microbial infection

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0169623 A1
- Document ID: US20190169623A1
- Status: Published application
- Kind: A1
- Application number: 16/209,706
- Filed: 2018-12-04
- Published: 2019-06-06
- Earliest claimed: 2017-12-05
- Assignees: BioPlx, Inc.
- Applicants: BioPlx, Inc.
- Inventors: Timothy W. Starzl; Todd D. Turner; Ravi S. V. Starzl
- Web page: https://patentgrep.com/patent/US20190169623A1

## CPC

- C12N 15/74: Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
- A61K 35/74: Bacteria (therapeutic use of a bacterial protein A61K38/00)
- A61K 35/741: Probiotics (probiotic yeast, e.g. saccharomyces A61K36/06)
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 31/04: Antibacterial agents
- C07K 14/245: Escherichia (G)
- C07K 14/31: from Staphylococcus (G)
- C12N 1/20: Bacteria; Culture media therefor
- C12N 9/16: acting on ester bonds (3.1)
- C12N 15/09: Recombinant DNA-technology
- C12N 15/63: Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N 15/64: General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
- C12N 15/77: for Corynebacterium; for Brevibacterium
- C12N 15/78: for Pseudomonas
- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61K 2035/11: {Medicinal preparations comprising living procariotic cells}
- A61K 2035/115: {Probiotics}
- C12N 2820/002: inducible or controllable
- C12N 2820/55: from bacteria
- C12N 2830/55: from bacteria
- C12N 2840/002: controllable or inducible
- C12N 2840/55: from bacteria
- C12Y 301/21004: Type II site-specific deoxyribonuclease (3.1.21.4)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12Y: ENZYMES

## Abstract

Methods and compositions are provided for durably influencing microbiological ecosystems (microbiomes) in a subject in order to prevent infection and reduce recurrence of infection by microorganisms. In some embodiments, compositions and methods are provided for the creation and use of molecularly-modified bacterial strains with the potential to prevent a variety of microorganism infections.

## Claims

### Claim 1

A synthetic microorganism, comprising a recombinant nucleotide comprising
at least one kill switch molecular modification comprising
a first cell death gene operatively associated with
a first regulatory region comprising an inducible first promoter, wherein
the first inducible promoter exhibits conditionally high level gene expression of the recombinant nucleotide in response to exposure to blood, serum, or plasma of at least three fold increase of basal productivity.

### Claim 2 (depends on 1)

The synthetic microorganism of claim 1, wherein the synthetic microorganism further comprises
at least a second molecular modification (expression clamp) comprising
an antitoxin gene specific for the first cell death gene, wherein the antitoxin gene is operably associated with
a second regulatory region comprising a second promoter which is active (constitutive) upon dermal or mucosal colonization or in a complete media, but is not induced, induced less than 1.5-fold, or is repressed after exposure to blood, serum or plasma for at least 30 minutes.

### Claim 3 (depends on 1)

The method of claim 1, wherein the synthetic microorganism is derived from a target microorganism having the same genus and species as an undesirable microorganism.

### Claim 4 (depends on 1)

The synthetic microorganism of claim 1, wherein the first promoter is upregulated by at least 5-fold, at least 10-fold, at least 20-fold, at least 50-fold, or at least 100-fold within at least 30 min, 60 min, 90 min, 120 min, 180 min, 240 min, 300 min, or at least 360 min following exposure to blood, serum, or plasma.

### Claim 5 (depends on 1)

The synthetic microorganism of claim 1, wherein the first promoter is not induced, induced less than 1.5 fold, or is repressed in the absence of blood, serum, or plasma.

### Claim 6 (depends on 2)

The synthetic microorganism of claim 2, wherein the second regulatory region comprising a second promoter is active upon dermal or mucosal colonization or in TSB media, but is repressed at least 2 fold upon exposure to blood, serum or plasma after a period of time selected from the group consisting of the group consisting of at least 30 min, 60 min, 90 min, 120 min, 180 min, 240 min, 300 min, and at least 360 min.

### Claim 7 (depends on 1)

The synthetic microorganism of claim 1, wherein measurable average cell death of the synthetic microorganism occurs within at least a preset period of time following induction of the first promoter.

### Claim 8 (depends on 7)

The synthetic microorganism of claim 7, wherein the measurable average cell death occurs within at least a preset period of time selected from the group consisting of within at least 1, 5, 15, 30, 60, 90, 120, 180, 240, 300, or 360 min minutes following exposure to blood, serum, or plasma.

### Claim 9 (depends on 8)

The synthetic microorganism of claim 8, wherein the measurable average cell death is at least a 50% cfu, at least 70%, at least 80%, at least 90%, at least 95%, at least 99%, at least 99.5%, at least 99.8%, or at least 99.9% cfu count reduction following the preset period of time.

### Claim 10 (depends on 1)

The synthetic microorganism of claim 1, wherein the kill switch molecular modification reduces or prevents infectious growth of the synthetic microorganism under systemic conditions in the subject.

### Claim 11 (depends on 1)

The synthetic microorganism of claim 1, wherein the at least one molecular modification is integrated to a chromosome of the synthetic microorganism.

### Claim 12 (depends on 3)

The synthetic microorganism of claim 3, wherein the target microorganism is susceptible to at least one antimicrobial agent.

### Claim 13 (depends on 12)

The synthetic microorganism of claim 12, wherein the target microorganism is selected from a bacterial, fungal, or protozoal target microorganism.

### Claim 14 (depends on 13)

The method of claim 13, wherein the target microorganism is a bacterial species capable of colonizing a dermal and/or mucosal niche and is a member of a genus selected from the group consisting of Acinetobacter, Corynebacterium, Cutibacterium, Staphylococcus, Streptococcus, Propionibacterium, and Pseudomonas.

### Claim 15 (depends on 14)

The synthetic microorganism of claim 14, wherein synthetic microorganism is derived from a Staphylococcus aureus strain.

### Claim 16 (depends on 15)

The synthetic microorganism of claim 15, wherein the cell death gene is selected from the group consisting of sprA1, sprA2, kpn1, sma1, sprG, relF, rsaE, yoeB, mazF, yefM, or lysostaphin toxin gene.

### Claim 17 (depends on 16)

The synthetic microorganism of claim 16, wherein the cell death gene comprises a nucleotide sequence selected from the group consisting of SEQ ID NOs: 122, 124, 125, 126, 127, 128, 274, 275, 284, 286, 288, 290, 315, and 317, or a substantially identical nucleotide sequence.

### Claim 18 (depends on 16)

The synthetic microorganism of claim 16, wherein the inducible first promoter comprises or is derived from a gene selected from the group consisting of isdA (iron-regulated surface determinant protein A), isdB (iron-regulated surface determinant protein B), isdG (heme-degrading monooxygenase), hlgA (gamma-hemolysin component A), hlgA1 (gamma-hemolysin), hlgA2 (gamma-hemolysin), hlgB (gamma-hemolysin component B), hrtAB (heme-regulated transporter), sbnC (luc C family siderophore biosyntheis protein), sbnD, sbnI, sbnE (lucA/lucC family siderophore biosynthesis protein), isdI, lrgA (murein hydrolase regulator A), lrgB (murein hydrolase regulator B), ear (Ear protein), fhuA (ferrichrome transport ATP-binding protein fhuA), fhuB (ferrichrome transport permease), hlb (phospholipase C), heme ABC transporter 2 gene, heme ABC transporter gene, isd ORF3, sbnF, alanine dehydrogenase gene, diaminopimelate decarboxylase gene, iron ABC transporter gene, threonine dehydratase gene, siderophore ABC transporter gene, SAM dep Metrans gene, HarA, splF (serine protease SplF), splD (serine protease SplD), dps (general stress protein 20U), SAUSA300_2617 (putative cobalt ABC transporter, ATP-binding protein), SAUSA300_2268 (sodium/bile acid symporter family protein), SAUSA300_2616 (cobalt family transport protein), srtB (Sortase B), sbnA (probable siderophore biosynthesis protein sbnA), sbnB, sbnG, leuA (2-isopropylmalate synthase amino acid biosynthetic enzyme), sstA (iron transport membrane protein), sirA (iron ABC transporter substrate-binding protein), isdA (heme transporter), and spa (Staphyloccocal protein A).

### Claim 19 (depends on 18)

The synthetic microorganism of claim 18, wherein the first promoter comprises a nucleotide sequence selected from the group consisting of SEQ ID NO: 114, 115, 119, 120, 121, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, and 163, or a substantially identical nucleotide sequence thereof.

### Claim 20 (depends on 16)

The synthetic microorganism of claim 16, wherein the antitoxin gene encodes an antisense RNA sequence capable of hybridizing with at least a portion of the first cell death gene.

### Claim 21 (depends on 20)

The synthetic microorganism of claim 20, wherein the antitoxin gene is selected from the group consisting of a sprA1 antitoxin gene, sprA2 antitoxin gene, sprG antitoxin gene or sprF, holin antitoxin gene, 187-lysK antitoxin gene, yefM antitoxin gene, lysostaphin antitoxin gene, or mazE antitoxin gene, kpn1 antitoxin gene, sma1 antitoxin gene, relF antitoxin gene, rsaE antitoxin gene, or yoeB antitoxin gene, respectively.

### Claim 22 (depends on 21)

The synthetic microorganism of claim 21, wherein the antitoxin gene comprises a nucleotide sequence selected from the group consisting of SEQ ID NOs: 273, 306, 307, 308, 309, 310, 311, 312, 314, 319, or 322, or a substantially identical nucleotide sequence.

### Claim 23 (depends on 21)

The synthetic microorganism of claim 21, wherein the second promoter comprises or is derived from a gene selected from the group consisting of clfB (Clumping factor B), sceD (autolysin, exoprotein D), walKR (virulence regulator), atlA (Major autolysin), oatA (O-acetyltransferase A); phosphoribosylglycinamide formyltransferase gene, phosphoribosylaminoimidazole synthetase gene, amidophosphoribosyltransferase gene, phosphoribosylformylglycinamidine synthase gene, phosphoribosylformylglycinamidine synthase gene, phosphoribosylaminoimidazole-succinocarboxamide gene, trehalose permease IIC gen, DeoR faimly transcriptional regulator gene, phosphofructokinase gene, PTS fructose transporter subunit IIC gene, galactose-6-phosphate isomerase gene, NarZ, NarH, NarT, alkylhydroperoxidase gene, hypothetical protein gene, DeoR trans factor gene, lysophospholipase gene, protein disaggregation chaperon gene, alkylhydroperoxidase gene, phosphofructokinase gene, gyrB, sigB, and rho.

### Claim 24 (depends on 23)

The synthetic microorganism of claim 23, wherein the second promoter is a PclfB (clumping factor B) and comprises a nucleotide sequence of SEQ ID NO: 117, 118, 129 or 130, or a substantially identical nucleotide sequence thereof.

### Claim 25 (depends on 1)

The synthetic microorganism according to claim 1, further comprising a molecular modification selected from the group consisting of a virulence block molecular modification, and nanofactory molecular modification.

### Claim 26 (depends on 25)

The synthetic microorganism of claim 25, wherein the virulence block molecular modification prevents horizontal gene transfer of genetic material from the undesirable microorganism.

### Claim 27 (depends on 25)

The synthetic microorganism of claim 25, wherein the nanofactory molecular modification comprises an insertion of a gene that encodes, a knock out of a gene that encodes, or a genetic modification of a gene that encodes a product selected from the group consisting of an enzyme, amino acid, metabolic intermediate, and a small molecule.

### Claim 28 (depends on 1)

A composition comprising an effective amount of the synthetic microorganism of claim 1, and a pharmaceutically acceptable carrier, diluent, emollient, binder, excipient, lubricant, sweetening agent, flavoring agent, wetting agent, preservative, buffer, or absorbent, or a combination thereof.

### Claim 29 (depends on 28)

The pharmaceutical composition of claim 28, further comprising a nutrient, prebiotic, commensal, and/or probiotic bacterial species.

### Claim 30 (depends on 28)

A single dose unit comprising the composition of claim 28.

### Claim 31 (depends on 30)

The single dose unit of claim 30, comprising at least 105, at least 106, at least 107, at least 108, at least 109, at least 1010 CFU, or at least 1011 of the synthetic strain and a pharmaceutically acceptable carrier.

### Claim 32 (depends on 31)

The dose unit of claim 31 formulated for topical administration.

### Claim 33

(canceled)

### Claim 34

A method for eliminating and preventing the recurrence of a undesirable microorganism in a subject hosting a microbiome, comprising:
a. decolonizing the host microbiome; and
b. durably replacing the undesirable microorganism by administering to the subject a synthetic microorganism comprising at least one element imparting a non-native attribute, wherein the synthetic microorganism is capable of durably integrating to the host microbiome, and occupying the same niche in the host microbiome as the undesirable microorganism.

### Claim 35 (depends on 34)

The method of claim 34, wherein the decolonizing is performed on at least one site in the subject to substantially reduce or eliminate the detectable presence of the undesirable microorganism from the at least one site.

### Claim 36 (depends on 35)

The method of claim 35, wherein the detectable presence of the undesirable microorganism is determined by a method comprising a phenotypic method and/or a genotypic method, optionally wherein the phenotypic method is selected from the group consisting of biochemical reactions, serological reactions, susceptibility to anti-microbial agents, susceptibility to phages, susceptibility to bacteriocins, and/or profile of cell proteins, and optionally
wherein the genotypic method is selected from the group consisting of hybridization, plasmids profile, analysis of plasmid polymorphism, restriction enzymes digest, reaction and separation by Pulsed-Field Gel Electrophoresis (PFGE), ribotyping, polymerase chain reaction (PCR) and its variants, Ligase Chain Reaction (LCR), and Transcription-based Amplification System (TAS).

### Claim 37 (depends on 35)

The method of claim 35, wherein the niche is a dermal or mucosal environment that allows stable colonization of the undesirable microorganism at the at least one site.

### Claim 38 (depends on 37)

The method of claim 37, wherein the ability to durably integrate to the host microbiome is determined by detectable presence of the synthetic microorganism at the at least one site for a period of at least two weeks, at least four weeks, at least six weeks, at least eight weeks, at least ten weeks, at least 12 weeks, at least 16 weeks, at least 26 weeks, at least 30 weeks, at least 36 weeks, at least 42 weeks, or at least 52 weeks after the administering step.

### Claim 39 (depends on 38)

The method of claim 38, wherein the ability to durably replace the undesirable microorganism is determined by the absence of detectable presence of the undesirable microorganism at the at least one site for a period of at least two weeks, at least four weeks, at least six weeks, at least eight weeks, at least ten weeks, at least 12 weeks, at least 16 weeks, at least 26 weeks, at least 30 weeks, at least 36 weeks, at least 42 weeks, or at least 52 weeks after the administering step.

### Claim 40 (depends on 39)

The method of claim 39, wherein the ability to occupy the same niche is determined by absence of co-colonization of the undesirable microorganism and the synthetic microorganism at the at least one site after the administering step,
optionally wherein the absence of co-colonization is determined at least one week, at least two weeks, at least four weeks, at least six weeks, at least eight weeks, at least ten weeks, at least 12 weeks, at least 16 weeks, at least 26 weeks, at least 30 weeks, at least 36 weeks, at least 42 weeks, or at least 52 weeks after the administering step.

### Claim 41 (depends on 34)

The method of claim 34, wherein the at least one element imparting the non-native attribute is durably incorporated to the synthetic microorganism.

### Claim 42 (depends on 41)

The method of claim 41, wherein the at least one element imparting the non-native attribute is durably incorporated to the host microbiome via the synthetic microorganism.

### Claim 43 (depends on 41)

The method of claim 41, wherein the at least one element imparting the non-native attribute is selected from the group consisting of kill switch molecular modification, virulence block molecular modification, metabolic modification, and nano factory molecular modification.

### Claim 44 (depends on 43)

The method of claim 43, wherein the molecular modification is integrated to a chromosome of the synthetic microorganism.

### Claim 45 (depends on 43)

The method of claim 43, wherein the synthetic microorganism comprises a virulence block molecular modification that prevents horizontal gene transfer of genetic material from the undesirable microorganism.

### Claim 46 (depends on 43)

The method of claim 43, wherein the synthetic microorganism comprises a kill switch molecular modification that reduces or prevents infectious growth of the synthetic microorganism under systemic conditions in the subject.

### Claim 47 (depends on 43)

The method of claim 43, wherein the synthetic microorganism is derived from a target microorganism having the same genus and species as the undesirable microorganism.

### Claim 48 (depends on 43)

The method of claim 43, wherein the synthetic microorganism is derived from a target microorganism that has the ability to biomically integrate with the decolonized host microbiome.

### Claim 49 (depends on 43)

The method of claim 43, wherein the synthetic microorganism is derived from a target microorganism isolated from the host microbiome.

### Claim 50 (depends on 48)

The method of claim 48, wherein the target microorganism is susceptible to at least one antimicrobial agent.

### Claim 51 (depends on 50)

The method of claim 50, wherein the target microorganism is selected from a bacterial, fungal, or protozoal target microorganism.

### Claim 52 (depends on 51)

The method of claim 51, wherein the target microorganism is a bacterial species capable of colonizing a dermal and/or mucosal niche and is a member of a genus selected from the group consisting of Acinetobacter, Corynebacterium, Cutibacterium, Staphylococcus, Streptococcus, Propionibacterium, and Pseudomonas.

### Claim 53 (depends on 52)

The method of claim 52, wherein the target microorganism is selected from the group consisting of Acinetobacter johnsonii, Acinetobacter baumannii, Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus lugdunensis, Staphylococcus warneri, Staphylococcus saprophyticus, Corynebacterium acnes, Corynebacterium striatum, Corynebacterium diphtheriae, Corynebacterium minutissimum, Cutibacterium acnes, Propionibacterium acnes, Propionibacterium granulosum, Streptococcus pyogenes, Streptococcus aureus, Streptococcus agalactiae, Streptococcus mitis, Streptococcus viridans, Streptococcus pneumoniae, Streptococcus anginosis, Steptococcus constellatus, Streptococcal intermedius, Streptococcus agalactiae, Pseudomonas aeruginosa, Pseudomonas oryzihabitans, Pseudomonas stutzeri, Pseudomonas putida, and Pseudomonas fluorescens, optionally wherein the target strain is a Staphylococcus aureus 502a strain or RN4220 strain.

### Claim 54 (depends on 46)

The method of claim 46, wherein the synthetic microorganism kill switch molecular modification comprises a first cell death gene operably linked to a first regulatory region comprising a first inducible promoter.

### Claim 55 (depends on 54)

The method of claim 54, wherein the first promoter is activated (induced) by a change in state in the microorganism environment in contradistinction to the normal physiological (niche) conditions at the at least one site in the subject.

### Claim 56 (depends on 55)

The method of claim 55, wherein measurable average cell death of the synthetic microorganism occurs within at least a preset period of time following induction of the first promoter.

### Claim 57 (depends on 56)

The method of claim 56, wherein the measurable average cell death occurs within at least a preset period of time selected from the group consisting of within at least 1, 5, 15, 30, 60, 90, 120, 180, 240, 300, or 360 min minutes following change of state.

### Claim 58 (depends on 57)

The method of claim 57, wherein the measurable average cell death is at least a 50% cfu, at least 70%, at least 80%, at least 90%, at least 95%, at least 99%, at least 99.5%, at least 99.8%, or at least 99.9% cfu count reduction following the preset period of time.

### Claim 59 (depends on 55)

The method of claim 55, wherein the change in state is selected from one or more of pH, temperature, osmotic pressure, osmolality, oxygen level, nutrient concentration, blood concentration, plasma concentration, serum concentration, metal concentration, chelated metal concentration, change in composition or concentration of one or more immune factors, mineral concentration, and electrolyte concentration.

### Claim 60 (depends on 59)

The method of claim 59, wherein the change in state is a higher concentration of and/or change in composition of blood, serum, plasma, or heme compared to normal physiological (niche) conditions at the at least one site in the subject.

### Claim 61 (depends on 60)

The method of claim 60, wherein the first promoter is a blood, serum, plasma, and/or heme responsive promoter.

### Claim 62 (depends on 60)

The method of claim 60, wherein the first promoter is upregulated by at least 1.5 fold, at least 3-fold, at least 5-fold, at least 10-fold, at least 20-fold, at least 50-fold, or at least 100-fold within a period of time selected from the group consisting of at least 30 min, 60 min, 90 min, 120 min, 180 min, 240 min, 300 min, and at least 360 min following the change of state.

### Claim 63 (depends on 62)

The method of claim 62, wherein the first promoter is not induced, induced less than 1.5 fold, or is repressed in the absence of the change of state.

### Claim 64 (depends on 63)

The method of claim 63, wherein the first promoter is induced at least 1.5, 2, 3, 4, 5 or at least 6 fold within a period of time in the presence of serum or blood.

### Claim 65 (depends on 64)

The method of claim 64, wherein the first promoter is not induced, induced less than 1.5 fold, or repressed under the normal physiological (niche) conditions at the at least one site.

### Claim 66 (depends on 64)

The method of claim 64, wherein the first promoter is not induced, induced less than 1.5 fold, or is repressed in the absence of blood, serum, plasma, or heme.

### Claim 67 (depends on 54)

The method of claim 54, wherein the synthetic microorganism is derived from a target microorganism that is a Staphylococcus aureus strain, and wherein the first promoter is derived from a gene selected from the group consisting of isdA (iron-regulated surface determinant protein A), isdB (iron-regulated surface determinant protein B), isdG (heme-degrading monooxygenase), hlgA (gamma-hemolysin component A), hlgA1 (gamma-hemolysin), hlgA2 (gamma-hemolysin), hlgB (gamma-hemolysin component B), hrtAB (heme-regulated transporter), sbnC (luc C family siderophore biosyntheis protein), sbnD, sbnI, sbnE (lucA/lucC family siderophore biosynthesis protein), isdI, lrgA (murein hydrolase regulator A), lrgB (murein hydrolase regulator B), ear (Ear protein), fhuA (ferrichrome transport ATP-binding protein fhuA), fhuB (ferrichrome transport permease), hlb (phospholipase C), heme ABC transporter 2 gene, heme ABC transporter gene, isd ORF3, sbnF, alanine dehydrogenase gene, diaminopimelate decarboxylase gene, iron ABC transporter gene, threonine dehydratase gene, siderophore ABC transporter gene, SAM dep Metrans gene, HarA, splF (serine protease SplF), splD (serine protease SplD), dps (general stress protein 20U), SAUSA300_2617 (putative cobalt ABC transporter, ATP-binding protein), SAUSA300_2268 (sodium/bile acid symporter family protein), SAUSA300_2616 (cobalt family transport protein), srtB (Sortase B), sbnA (probable siderophore biosynthesis protein sbnA), sbnB, sbnG, leuA (2-isopropylmalate synthase amino acid biosynthetic enzyme), sstA (iron transport membrane protein), sirA (iron ABC transporter substrate-binding protein), isdA (heme transporter), and spa (Staphyloccocal protein A).

### Claim 68 (depends on 67)

The method of claim 67, wherein the first promoter is derived from or comprises a nucleotide sequence selected from the group consisting of SEQ ID NO: 114, 115, 119, 120, 121, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, and 163, or a substantially identical nucleotide sequence thereof.

### Claim 69 (depends on 67)

The method of claim 67, wherein the undesirable microorganism is a Staphylococcus aureus strain, and wherein the detectable presence is measured by a method comprising obtaining a sample from the at least one site of the subject, contacting a chromogenic agar with the sample, incubating the contacted agar and counting the positive cfus of the bacterial species after a predetermined period of time.

### Claim 70 (depends on 69)

The method of claim 69, wherein the cell death gene is selected from a toxin gene selected from the group consisting of sprA1, sprA2, kpn1, sma1, sprG, relF, rsaF, yoeB, mazF, yefM, and lysostaphin toxin gene.

### Claim 71 (depends on 70)

The method of claim 70, wherein the cell death gene comprises a nucleotide sequence selected from the group consisting of SEQ ID NO: 122, 124, 125, 126, 127, 128, 274, 275, 284, 286, 288, 290, 315, and 317, or a substantially identical nucleotide sequence.

### Claim 72 (depends on 67)

The method of claim 67, wherein the synthetic microorganism further comprises an expression clamp molecular modification comprising an antitoxin gene specific for the first cell death gene, wherein the antitoxin gene is operably linked to a second regulatory region comprising a second promoter which is active upon dermal or mucosal colonization or in TSB media, but is repressed at least 2 fold upon exposure to blood, serum or plasma after a period of time selected from the group consisting of the group consisting of at least 30 min, 60 min, 90 min, 120 min, 180 min, 240 min, 300 min, and at least 360 min.

### Claim 73 (depends on 72)

The method of claim 72, wherein the antitoxin gene encodes an antisense RNA sequence capable of hybridizing with at least a portion of the first cell death gene.

### Claim 74 (depends on 73)

The method of claim 73, wherein the antitoxin gene is selected from the group consisting of a sprA1 antitoxin gene, sprA2 antitoxin gene, sprG antitoxin gene or sprF, holin antitoxin gene, 187-lysK antitoxin gene, yefM antitoxin gene, lysostaphin antitoxin gene, or mazE antitoxin gene, kpn1 antitoxin gene, sma1 antitoxin gene, relF antitoxin gene, rsaE antitoxin gene, or yoeB antitoxin gene, respectively.

### Claim 75 (depends on 74)

The method of claim 74, wherein the antitoxin gene comprises a nucleotide sequence selected from the group consisting of SEQ ID NOs: 273, 306, 307, 308, 309, 310, 311, 312, 314, 319, or 322 or a substantially identical nucleotide sequence

### Claim 76 (depends on 74)

The method of claim 74, wherein the second promoter is derived from a gene selected from the group consisting of clfB (Clumping factor B), sceD (autolysin, exoprotein D), walKR (virulence regulator), atlA (Major autolysin), oatA (O-acetyltransferase A); phosphoribosylglycinamide formyltransferase gene, phosphoribosylaminoimidazole synthetase gene, amidophosphoribosyltransferase gene, phosphoribosylformylglycinamidine synthase gene, phosphoribosylformylglycinamidine synthase gene, phosphoribosylaminoimidazole-succinocarboxamide gene, trehalose permease IIC gen, DeoR faimly transcriptional regulator gene, phosphofructokinase gene, PTS fructose transporter subunit IIC gene, galactose-6-phosphate isomerase gene, NarZ, NarH, NarT, alkylhydroperoxidase gene, hypothetical protein gene, DeoR trans factor gene, lysophospholipase gene, protein disaggregation chaperon gene, alkylhydroperoxidase gene, phosphofructokinase gene, gyrB, sigB, and rho.

### Claim 77 (depends on 76)

The method of claim 76, wherein the second promoter is a PclfB (clumping factor B) and comprises a nucleotide sequence of SEQ ID NO: 117, 118, 129 or 130, or a substantially identical nucleotide sequence thereof.

### Claim 78 (depends on 34)

The method of claim 34, wherein the decolonizing step comprises topically administering a decolonizing agent to the at least one site in the subject to reduce or eliminate the presence of the undesirable microorganism from the at least one site.

### Claim 79 (depends on 78)

The method of claim 78, wherein the decolonizing step comprises topical administration of the decolonizing agent, wherein no systemic antimicrobial agent is simultaneously administered.

### Claim 80 (depends on 79)

The method of claim 79, wherein no systemic antimicrobial agent is administered within one week, two weeks, three weeks, one month, two months, three months, six months, or one year of the first topical administration of the decolonizing agent.

### Claim 81 (depends on 79)

The method of claim 79, wherein the decolonizing agent is selected from the group consisting of a disinfectant, bacteriocide, antiseptic, astringent, and antimicrobial agent.

### Claim 82 (depends on 81)

The method of claim 81, wherein the decolonizing agent is selected from the group consisting of alcohols (ethyl alcohol, isopropyl alcohol), aldehydes (glutaraldehyde, formaldehyde, formaldehyde-releasing agents (noxythiolin=oxymethylenethiourea, tauroline, hexamine, dantoin), o-phthalaldehyde), anilides (triclocarban=TCC=3,4,4′-triclorocarbanilide), biguanides (chlorhexidine, alexidine, polymeric biguanides (polyhexamethylene biguanides with MW>3,000 g/mol, vantocil), diamidines (propamidine, propamidine isethionate, propamidine dihydrochloride, dibromopropamidine, dibromopropamidine isethionate), phenols (fentichlor, p-chloro-m-xylenol, chloroxylenol, hexachlorophene), bis-phenols (triclosan, hexachlorophene), chloroxylenol (PCMX), quaternary ammonium compounds (cetrimide, benzalkonium chloride, cetyl pyridinium chloride), silver compounds (silver sulfadiazine, silver nitrate), peroxy compounds (hydrogen peroxide, peracetic acid, benzoyl peroxide), iodine compounds (povidone-iodine, poloxamer-iodine, iodine), chlorine-releasing agents (sodium hypochlorite, hypochlorous acid, chlorine dioxide, sodium dichloroisocyanurate, chloramine-T), copper compounds (copper oxide), isotretinoin, sulfur compounds, botanical extracts (Melaleuca spp. (tea tree oil), (Vaccinium spp. (e.g., A-type proanthocyanidins), Cassia fistula Linn, Baekea frutesdens L., Melia azedarach L., Muntingia calabura, Vitis vinifera L, Terminalia avicennioides Guill & Perr., Phylantus discoideus muel. Muel-Arg., Ocimum gratissimum Linn., Acalypha wilkesiana Muell-Arg., Hypericum pruinatum Boiss. & Bal., Hypericum olimpicum L. and Hypericum sabrum L., Hamamelis virginiana (witch hazel), Clove oil, Eucalyptus spp., rosemarinus officinalis spp. (rosemary), thymus spp. (thyme), Lippia spp. (oregano), lemongrass spp., cinnamomum spp., geranium spp., lavendula spp.), aminolevulonic acid, and topical antibiotic compounds (bacteriocins; mupirocin, bacitracin, neomycin, polymyxin B, gentamicin).

### Claim 83 (depends on 81)

The method of claim 81, wherein the antimicrobial agent is selected from the group consisting of vancomycin, cefazolin, cepahalothin, cephalexin, linezolid, daptomycin, clindamycin, lincomycin, mupirocin, bacitracin, neomycin, polymyxin B, gentamicin, prulifloxacin, ulifloxacin, fidaxomicin, minocyclin, metronidazole, metronidazole, sulfamethoxazole, ampicillin, trimethoprim, ofloxacin, norfloxacin, tinidazole, norfloxacin, omidazole, levofloxacin, nalidixic acid, ceftriaxone, azithromycin, cefixime, ceftriaxone, cefalexin, ceftriaxone, rifaximin, ciprofloxacin, norfloxacin, ofloxacin, levofloxacin, gatifloxacin, gemifloxacin, prufloxacin, ulifloxacin, moxifloxacin, nystatin, amphotericin B, flucytosine, ketoconazole, posaconazole, clotrimazole, voriconazole, griseofulvin, miconazole nitrate, and fluconazole.

### Claim 84 (depends on 78)

The method of claim 78, wherein the decolonizing comprises topically administering the decolonizing agent at least one, two, three, four, five or six or more times prior to the replacing step.

### Claim 85 (depends on 84)

The method of claim 84, wherein the decolonizing step comprises administering the decolonizing agent to the at least one host site in the subject from one to six or more times or two to four times at intervals of between 0.5 to 48 hours apart, and wherein the replacing step is performed after the final decolonizing step.

### Claim 86 (depends on 85)

The method of claim 85, wherein the replacing step comprises initial topical administration of a composition comprising at least 105, at least 106, at least 107, at least 108, at least 109, at least 1010 CFU, or at least 1011 of the synthetic strain and a pharmaceutically acceptable carrier to the at least one host site in the subject.

### Claim 87 (depends on 86)

The method of claim 86, wherein the initial replacing step is performed within 12 hours, 24 hours, 36 hours, 2 days, 3 days, 4 days, 5 days, 6 days or 7 days of the decolonizing step.

### Claim 88 (depends on 86)

The method of claim 86, wherein the replacing step is repeated at intervals of no more than once every two weeks to six months following the final decolonizing step.

### Claim 89 (depends on 86)

The method of claim 86, wherein the decolonizing step and the replacing step is repeated at intervals of no more than once every two weeks to six months.

### Claim 90 (depends on 88)

The method of claim 88, wherein the replacing comprises administering the synthetic microorganism to the at least one site at least one, two, three, four, five, six, seven, eight, nine, or ten times.

### Claim 91 (depends on 90)

The method of claim 90, wherein the replacing comprises administering the synthetic microorganism to the at least one site no more than one, no more than two, no more than three times, or no more than four times per month

### Claim 92 (depends on 34)

The method of claim 34, further comprising
promoting colonization of the synthetic microorganism in the subject.

### Claim 93 (depends on 92)

The method of claim 92, wherein the promoting colonization of the synthetic microorganism in the subject comprises administering to the subject a promoting agent, optionally where the promoting agent is a nutrient, prebiotic, commensal, stabilizing agent, humectant, and/or probiotic bacterial species.

### Claim 94 (depends on 93)

The method of claim 93, wherein the promoting comprises administering from 106 to 1010 cfu, or 107 to 109 cfu of the probiotic bacterial species to the subject after the initial decolonizing step.

### Claim 95 (depends on 93)

The method of claim 93, wherein the nutrient is selected from sodium chloride, lithium chloride, sodium glycerophosphate, phenylethanol, mannitol, tryptone, peptide, and yeast extract.

### Claim 96 (depends on 93)

The method of claim 93, wherein the prebiotic is selected from the group consisting of short-chain fatty acids (acetic acid, propionic acid, butyric acid, isobutyric acid, valeric acid, isovaleric acid), glycerol, pectin-derived oligosaccharides from agricultural by-products, fructo-oligosaccarides (e.g., inulin-like prebiotics), galacto-oligosaccharides (e.g., raffinose), succinic acid, lactic acid, and mannan-oligosaccharides.

### Claim 97 (depends on 93)

The method of claim 93, wherein the probiotic is selected from the group consisting of Bifidobacterium breve, Bifidobacterium bifidum, Bifidobacterium lactis, Bifidobacterium infantis, Bifidobacterium breve, Bifidobacterium longum, Lactobacillus reuteri, Lactobacillus paracasei, Lactobacillus plantarum, Lactobacillus johnsonii, Lactobacillus rhamnosus, Lactobacillus acidophilus, Lactobacillus salivarius, Lactobacillus casei, Lactobacillus plantarum, Lactococcus lactis, Streptococcus thermophiles, and Enterococcus fecalis.

### Claim 98 (depends on 93)

The method of claim 93, wherein the commensal is selected from the group consisting of Acinetobacter johnsonii, Acinetobacter baumannii, Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus lugdunensis, Staphylococcus warneri, Staphylococcus saprophyticus, Corynebacterium acnes, Corynebacterium striatum, Corynebacterium diphtheriae, Corynebacterium minutissimum, Cutibacterium acnes, Propionibacterium acnes, Propionibacterium granulosum, Streptococcus pyogenes, Streptococcus aureus, Streptococcus agalactiae, Streptococcus mitis, Streptococcus viridans, Streptococcus pneumoniae, Streptococcus anginosis, Steptococcus constellatus, Streptococcal intermedius, Streptococcus agalactiae, Pseudomonas aeruginosa, Pseudomonas oryzihabitans, Pseudomonas stutzeri, Pseudomonas putida, and Pseudomonas fluorescens.

### Claim 99 (depends on 43)

The method of claim 43, wherein the undesirable microorganism is an antimicrobial agent-resistant microorganism.

### Claim 100 (depends on 99)

The method of claim 99, wherein the antimicrobial agent-resistant microorganism is an antibiotic resistant bacteria.

### Claim 101 (depends on 99)

The method of claim 99, wherein the antibiotic-resistant bacteria is a Gram-positive bacterial species selected from the group consisting of a Streptococcus spp., Cutibacterium spp., and a Staphylococcus spp.

### Claim 102 (depends on 101)

The method of claim 101, wherein the Streptococcus spp. is selected from the group consisting of Streptococcus pneumoniae, Steptococcus mutans, Streptococcus sobrinus, Streptococcus pyogenes, and Streptococcus agalactiae.

### Claim 103 (depends on 101)

The method of claim 101, wherein the Cutibacterium spp. is selected from the group consisting of Cutibacterium acnes subsp. acnes, Cutibacterium acnes subsp. defendens, and Cutibacterium acnes subsp. elongatum.

### Claim 104 (depends on 101)

The method of claim 101, wherein the Staphylococcus spp. is selected from the group consisting of Staphylococcus aureus, Staphylococcus epidermidis, and Staphylococcus saprophyticus.

### Claim 105 (depends on 104)

The method of claim 104, wherein the undesirable microorganism is a methicillin-resistant Staphylococcus aureus (MRSA) strain that contains a staphylococcal chromosome cassette (SCCmec types which encode one (SCCmec type I) or multiple antibiotic resistance genes (SCCmec type II and III), and/or produces a toxin.

### Claim 106 (depends on 105)

The method of claim 105, wherein the toxin is selected from the group consisting of a Panton-Valentine leucocidin (PVL) toxin, toxic shock syndrome toxin-1 (TSST-1), staphylococcal alpha-hemolysin toxin, staphylococcal beta-hemolysin toxin, staphylococcal gamma-hemolysin toxin, staphylococcal delta-hemolysin toxin, enterotoxin A, enterotoxin B, enterotoxin C, enterotoxin D, enterotoxin E, and a coagulase toxin.

### Claim 107 (depends on 43)

The method of claim 43, wherein the subject does not exhibit recurrence of the undesirable microorganism as evidenced by swabbing the subject at the at least one site for at least two weeks, at least two weeks, at least four weeks, at least six weeks, at least eight weeks, at least ten weeks, at least 12 weeks, at least 16 weeks, at least 24 weeks, at least 30 weeks, at least 36 weeks, at least 42 weeks, or at least 52 weeks after the administering step.

### Claim 108 (depends on 28)

A kit comprising in at least one container, the composition according to claim 28, and optionally at least a second container comprising a decolonizing agent, a sheet of instructions, at least a third container comprising a promoting agent, and/or an applicator.
